You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / SYNCOM FORMULATIONS (INDIA)

SYNCOM FORMULATIONS (INDIA)
Intrinsic Value | Fundamental Analysis

Returns | 1W : -5% , 1M : 39%,1Y : 660.4%
www.sfil.in
BOM : 524470     NSE :     
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward
Pledged Shares : None or < 25%
Oct 25,2021
Price(EOD): Rs. 10.19
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Affiliate Link.
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
SYNCOM FORMULATIONS (INDIA) -5% 39% 660.4%
SUN PHARMACEUTICAL INDUSTRIES -1.7% 5.6% 67.1%
DIVIS LABORATORIES -3.8% -4.1% 64.7%
DR REDDYS LABORATORIES -2.6% -2.5% -8.6%
CIPLA -0.5% -6.8% 17.3%
GLAND PHARMA -0.4% -4.8% NA
PIRAMAL ENTERPRISES -5.3% -6.4% 96.5%
CADILA HEALTHCARE -5.4% -12.1% 17.4%
TORRENT PHARMACEUTICALS 0.5% -0.6% 9.6%


FUNDAMENTAL ANALYSIS OF SYNCOM FORMULATIONS (INDIA)

 
Fundamentals Score
[ Q(TTM): Jun2021, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]
Show Me the Stocks with Fundamentals better than SYNCOM FORMULATIONS (INDIA) Plus/Pro


VALUATION OF SYNCOM FORMULATIONS (INDIA)

 
Valuation Score
[As on : Oct 25,2021 ]

Ratio Standalone
P/E
P/B
P/S
27.54
P/E Calculated based on EPS of 0.37
[ Mar2021 - Standalone Results ]

4.53
P/B Calculated based on Book Value of 2.25
[ Mar2021 - Standalone Results ]

3.17
P/S Calculated based on Revenues of 266.834 Cr
[ TTM - Standalone Results ]

Show Me the Stocks with Valuation better than SYNCOM FORMULATIONS (INDIA) Plus/Pro


FAIR VALUE OF SYNCOM FORMULATIONS (INDIA)

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
909%
245%
287%

SHARE PRICE MOMENTUM OF SYNCOM FORMULATIONS (INDIA)

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2021
2020
2019
Avg_3yrs
0.35
0.01
0.07
0.14
-
-
-
-
[Last Annual Data : Mar2021]

PLEDGED SHARES

Pledged Shares
0 %
As on : Sep2021

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Standalone Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-21.78%
-16.81%
-34.32%
-22.33%
75.34%
69.81%
80.69%
81.96%
QtrlyTrend
0
Latest Qtr: Jun2021

SYNCOM FORMULATIONS (INDIA) related INDICES

BSE Indices1W1M1Y
S&P BSE ALLCAP -2.8% 0.8% 59.9%
S&P BSE HEALTHCARE -3.2% -5.7% 27%
S&P BSE MIDSMALLCAP -5.4% -1.2% 82.5%
S&P BSE SMALL CAP -5.8% -1% 90.8%
No NSE index found

You may also like the below Video Courses


FAQ [Frequently Asked Questions]


Is SYNCOM FORMULATIONS (INDIA) good for long term investment?

As on 25-Oct-2021, the Fundamentals of SYNCOM FORMULATIONS (INDIA) look Poor and hence it may not be good for long term investment ! See Financial Performance of SYNCOM FORMULATIONS (INDIA) . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SYNCOM FORMULATIONS (INDIA) UnderValued or OverValued?

As on 25-Oct-2021, SYNCOM FORMULATIONS (INDIA) is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) ?

As on 25-Oct-2021, the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) is Rs. 2.63 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 1.01
Fair Value [Median EV / Sales Model] : Rs. 2.95
Fair Value [Median Price / Sales Model] : Rs. 2.63
Median Fair Value of SYNCOM FORMULATIONS (INDIA) : Rs. 2.63

Is SYNCOM FORMULATIONS (INDIA) trading at a Premium or Discount?

As on 25-Oct-2021, SYNCOM FORMULATIONS (INDIA) is trading at a Premium of 288% based on the estimates of Median Intrinsic Value!

What is the Financial Performance of Industry Peers of SYNCOM FORMULATIONS (INDIA) ?

Check out Annual Financials of Industry Peers
Share Price & Financials of SUN PHARMACEUTICAL INDUSTRIES LTD | BOM: 524715 | NSE: SUNPHARMA
Share Price & Financials of DIVIS LABORATORIES LTD | BOM: 532488 | NSE: DIVISLAB
Share Price & Financials of DR REDDYS LABORATORIES LTD | BOM: 500124 | NSE: DRREDDY
Share Price & Financials of CIPLA LTD | BOM: 500087 | NSE: CIPLA
Share Price & Financials of GLAND PHARMA LTD | BOM: 543245 | NSE: GLAND
Check out Quarterly Results of Industry Peers
Quarterly Results of SUN PHARMACEUTICAL INDUSTRIES LTD
Quarterly Results of DIVIS LABORATORIES LTD
Quarterly Results of DR REDDYS LABORATORIES LTD
Quarterly Results of CIPLA LTD
Quarterly Results of GLAND PHARMA LTD

What are the Frequent Comparisons in this Industry?

Compare Analytics
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
Browse Market Cap of Industry Peers
Market Cap of SUN PHARMACEUTICAL INDUSTRIES LTD
Market Cap of DIVIS LABORATORIES LTD
Market Cap of DR REDDYS LABORATORIES LTD
Market Cap of CIPLA LTD
Market Cap of GLAND PHARMA LTD

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z